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Abstract Total pancreatectomy is associated with short-
and long-term high complication rate and without evidence
of oncologic advantages. Several metabolic consequences
are co-related with the apancreatic state. The unstable dia-
betes related to the total resection of the pancreas expose
the patients to short- and long-term life-threatening com-
plications. Severe hypoglycemia is a short-term dangerous
complication that can also cause patients’ death. Chronic
complications of severe diabetes (cardiac and vascular
diseases, neuropathy, nephropathy, and retinopathy) are
also cause of morbidity, mortality and worsening of quality
of life. For this reasons the number of total pancreatec-
tomies performed has certainly decreased over time.
However, today there are still some indications for this
kind of procedures. Chronic pancreatitis untreatable with
conventional treatments, surgical treatment of precancer-
ous pancreatic lesions, surgical treatment of locally
advanced pancreatic cancer and the management of
patients with extraordinary high-risk pancreatic texture
after pancreaticoduodenectomy represent possible indica-
tions for total pancreatectomy and are analyzed in the
present paper.
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Introduction
At the beginning of the era of oncologic pancreatic surgery,
total pancreatectomy (TP) was used as a ‘‘radical procedure’’
for the surgical treatment of pancreatic cancer [1, 2]. How-
ever, new insights on pancreatic oncology, associated with
the evidence of the side effects of total pancreatectomy, have
made this procedure less appealing. The short- and long-term
morbidity and mortality associated with the apancreatic state
affecting these patients continue to be of concern today [3].
For these reasons, the complete removal of the pancreas is
not considered today a more ‘‘radical’’ operation for patients
suffering from pancreatic cancer and it cannot be considered
the standard of care for the surgical treatment of these
patients [4].
Even if the number of total pancreatectomies performed
has certainly decreased over time, today there are still some
indications for this procedure. Most of these are based more
on local or personal experience rather than on true evidence
and some data even show that the short- and long-term results
of TP are not much different than undergoing a partial
resection of the pancreas. A recent matched-pairs analysis of
TP and pancreaticoduodenectomy, for example, revealed
similar surgical outcome and long-term survival [5]. In the
last decades, new advances in pancreatic surgery and in
medical pancreatology have resulted in a new appraisal of TP
as a treatment alternative for some pancreatic diseases or as
technical option for some operative procedures.
In recent years, when major attention has been focused on
preemptive pancreatic surgery [6], the role of TP has again
been reevaluated. At the same time TP is proposed, with or
without simultaneous auto-islet transplantation, for some
types of chronic pancreatitis [7] and also for the treatment of
locally advanced pancreatic cancer requiring arterial resec-
tion and reconstruction [8]. Total pancreatectomy combined
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with autologous islet transplantation has also been proposed
for patients with a high-risk for complications resulting from
the pancreatic anastomosis [9].
The aim of this review paper is to offer a complete
overview of the outcome of TPs and to define the current
indication for this procedure.
Outcome of total pancreatectomy
Surgical outcome
Generally, TP is considered a safer procedure than pan-
creaticoduodenectomy in the perioperative setting since a
pancreatico-jejunostomy is not required. This implication
is the basis for concept that TP may be an option for
patients with a normal pancreas and a very high-risk for
leakage after reconstruction, to prevent major postoperative
complications. This theory has anyhow not been confirmed
by the literature data. A recent analysis made on the US
National Cancer Data Base [10] on 2582 patients who
underwent TP for pancreatic cancer showed a 30-day
mortality rate of 5.5 %. The same rate of short-term mor-
tality was observed by Billings and co-authors [11] in a
series of 99 consecutive TP, with the addition of 3 % of
late death related to hypoglycemic episodes. The same
authors investigated also the long-term QoL of 27 patients
included in the study, showing a decrease of QoL com-
pared with age- and gender-matched controls, but not
compared to patients with diabetes from other causes. Even
analyzing the recent data from the literature, it is quite
evident that TP are associated with a significant postoper-
ative morbidity and mortality, not inferior to partial pan-
createctomy, as showed in Table 1 [5, 9, 10, 12–17].
Metabolic consequences of total pancreatectomy
Several metabolic consequences are co-related with the
apancreatic state, which characterizes the patients who
underwent TP. Certainly, the most known and investigated
sequel is diabetes. As defined by the American Diabetes
Association, patients who underwent TP suffer from a type
3c diabetes, also called pancreatogenic diabetes [18]. In this
form of diabetes, the glycemic control may be labile due to
the loss of not only the insulin production, but particularly
due to the loss of glucagon secretion [19]. The combination
of insulin sensitivity and hypoglycemic unawareness, char-
acteristic of this condition, is known as ‘‘brittle’’ diabetes
[20]. It exposes patients who have undergone TP to short-
and long-term life-threatening complications. In a recent
series from Mayo Clinic, the large majority of patients
undergoing TP (89 %) required a complex insulin regimen to
maintain acceptable glycemic control. Seventy nine of them
experienced episodes of hypoglycemia and 41 % of severe
hypoglycemia. The resuscitation of these patients was pos-
sible by family members or co-workers only in 27 % of the
cases, while the remaining 73 % required medical inter-
vention or hospitalization [3]. Significant late mortality
(3 %) due to hypoglycemic episodes has been reported by
other authors [11]. The nonoptimal glycemic control is also
the cause for chronic complications in the specific target
organs. In the Mayo Clinic, the total cohort of patients who
underwent TP experienced retinopathy in 3 %, neuropathy
in 5 %, nephropathy in 4 %, cerebrovascular diseases in
1 %, cardiovascular diseases in 11 % [3].
The medical treatment of type 3c diabetes may be
challenging. Insulin infusion pumps seem to improve the
glycemic control and reduce the attacks of hypoglycemia
[21]. However, evidence is lacking on the effect of this
kind of treatment on the long-term complications of dia-
betes. The addition of glucagon injection to the insulin
regimen seems to be advantageous in reducing the hypo-
glycemic episodes, but so far, only limited evidence about
its usage is available [22].
Pancreatic exocrine insufficiency (PEI) is another conse-
quence of TP. Even with high dose of pancreatic enzyme
replacement therapy, a significant part of the patients who have
undergone TP still suffer from steatorrhea, with consequent
Table 1 Short-term outcome of
patients underwent TP
Author Year # Patients # IAT Overall morbidity (%) Overall mortality (%)
Johnston PC 2016 2582 N.A. N.A. 5.5
Balzano G 2015 28 28 57.1 7.1
Satoi S 2015 45 – 31.1 –
Chinnakotla S 2015 518 518 N.A. 9.2
Johnston PC 2015 18 18 50 N.A.
Wantabe Y 2015 23 – 43 4
Datta J 2015 64 – 45.3 1.6
Hartwig W 2015 434 – 37.6 7.8
Almond M 2014 80 – 46 12.5
Nikfarjam M 2014 15 – 87 8
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malabsorption, thus complicating further the already fragile
management of diabetes [23]. PEI requires a lifelong substi-
tutive treatment with pancreas enzymes [24]. However, the
enzyme substitution in the majority of patients might not be
enough to completely restore the normal digestion. A con-
siderable number of the patients are thus undertreated for this
problem, with underestimated and undiagnosed subclinical
malnutrition even in the absence of steatorrhea [25]. Further-
more, alteration of the gastrointestinal motility is a well-known
digestive disturbance associated with the development of
severe exocrine insufficiency, but its role in post-pancreatec-
tomy patients has not been investigated.
Liver steatosis is another complication considered to be
associated with TP. It has been demonstrated that it may
result in liver failure in some patients [26].
Quality of life (QoL) after total pancreatectomy
QoL after TP is a very difficult topic to investigate and
elaborate on. There are several and different instruments
for the QoL measurement. The indications for TP and its
associated procedures (i.e., auto-islet transplantation) are
also several and different, as well as the initial condition of
the patients and the expected long-term results and func-
tionality, making it difficult to unequivocally apply all
these instruments. In a recent small series Watanabe
defined the QoL of a group on patients who underwent TP
comparable to those of the national population, excluding
for one third of the patients that experienced diarrhea [14].
Billings and colleagues [11] investigated the QoL of 34
patients who underwent total pancreatectomy with three
different audit systems (SF-36, ADD QoL and EORTC
PAN-26). They concluded that QoL after pancreatectomy
is decreased compared with the age- and gender- matched
controls, but not with diabetic patients for other causes.
Indications for total pancreatectomy
Chronic pancreatitis
Chronic pancreatitis (CP) is a progressive chronic inflam-
mation of the pancreas that can be caused by several
etiological factors. Currently, a step-up approach (medical
treatment, endoscopic treatment, surgical treatment) for
patients suffering from CP has been recommended to be
the standard of care. The most common consequences of
chronic pancreatitis are abdominal pain and exocrine and
endocrine insufficiency. In case when the pain is associated
with ductal dilatation, a decompressive procedure is indi-
cated. In these cases surgery seems to be superior to
endoscopy according to recent studies [27]. In the case of
‘‘small-duct’’ CP in patients resistant to medical treatment,
TP with or without auto-islet transplantation has been
proposed [28, 29]. The same indication is present for
patients with hereditary pancreatitis who are at increased
risk for cancer development.
TP with auto-islet transplantation has received
increasing attention recently. The concept behind this
approach is interesting, because the procedure seems to
be safe and theoretically able to maintain good glycemic
control, thus avoiding one of the devastating complica-
tions of TP [30]. The rate of insulin independence after
auto-islet transplantation ranges between 24 and 40 % in
the largest series as reported in Table 2 [28, 31–33]. For
further, one third of the patients partial insulin depen-
dence is achieved providing a better and more
stable glycemic control. One of the most important
predictor factors of insulin independence seems to be the
quantity of the transplanted islets [28, 33]. For this
reason, the timing of surgery for chronic pancreatitis is
essential. Thus, in patients considered as candidates for
TP with auto-islet transplantation, surgery should per-
haps be considered earlier and certainly before the
endocrine function is compromised. Furthermore, this
procedure has shown even benefits in terms of the pain
control. In other series, the range of pain-free or nar-
cotic-independent patients is reported to be from 59 % to
80 % [28, 32]. The pain control seems to be stable over
time, too. Ong and co-workers [31] reported that only
16 % of patients who underwent TP with auto-islet
transplantation needed opiates at 5 years. For patients
with chronic pancreatitis who have with maintained
endocrine function but pain resistant to medical, endo-
scopic and surgical treatment, this option has shown also
an improved quality of life [32].
Table 2 Outcome of total pancreatectomy ? auto-islet transplantation for chronic pancreatitis
Author Year # Patients Insulin independent (%) Partial function (%) Insulin dependent (%)
Sutherland DR 2012 409 30 (3 years) 33 (3 years) 37 (3 years)
Walsh RM 2012 20 20 (not specified) – 80 % (not specified)
Ong SL 2009 50 40 (post-op) – –
Ahmad S 2005 118 40 (not specified) – 60 (not specified)
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Premalignant lesions
TP has been proposed as a preemptive treatment for
patients with a familial risk for pancreatic cancer [34].
Today, however, the prophylactic removal of the pancreas
in individuals with a family history of pancreatic cancer is
not recommended by neither national nor international
guidelines [35, 36]. Rather, the treatment of detected pre-
cancerous lesions is advised, by partial pancreatic resec-
tions. However, unlike IPMNs, Pan-INs still cannot be
detected by the current imaging modalities. This has raised
the concern that undetected precancerous lesions might be
left behind in the residual pancreas, thus leaning the choice
towards TP. In case of abnormalities diffusely involving
the pancreatic gland, in young patients and with high
familial risk, though, a total pancreatectomy might be
considered [37].
Intraductal papillary mucinous neoplasms of the pan-
creas (IPMNs) also comprise precancerous lesions that
potentially can progress into cancer. In accordance with the
emerging literature data and with the European and Inter-
national Guidelines, the majority of branch-duct IPMNs
can be managed conservatively without the need for sur-
gical resection [38, 39]. In contrast, the main-duct IPMNs
require resection in every patient fit for surgery [38, 39].
There is emerging evidence in the literature supporting the
indication for surgery even for relatively small dilatation of
the main pancreatic duct, as recommended by the European
Guidelines on Cystic Tumors of the Pancreas [40, 41].
When the dilatation of the duct is confined to a certain
segment, a partial pancreatectomy with a frozen section of
the resection margin is recommended [38]. The situation is
more complicated when the entire duct is dilated. In this
case, generally a pancreaticoduodenectomy with a frozen
section of the resection margin is advocated to determine
the extent of the resection [38]. The only scenario when
total pancreatectomy is recommended is in case of dif-
fusely extensive disease, with an advanced stage of dys-
plasia present in the entire duct. How reliable the frozen
section is in determining the extent of the grossly dys-
plastic changes in the duct is questionable, and for sure,
‘‘skip lesions’’ of the main pancreatic duct can be missed.
Pancreatoscopy, pre- or intraoperatively, can improve the
accuracy of defining the extent of the disease and poten-
tially better help select the candidates for a total pancrea-
tectomy [42] (Fig. 1).
Locally advanced pancreatic cancer
Even if the surgical treatment of locally advanced pan-
creatic cancer is currently not the standard of care, it did
receive more attention recently in the light of the more
promising results of new neoadjuvant treatments [43]. In
selected cases, surgery for locally advanced pancreatic
cancer is also supported by the international scientific
community [44]. When an arterial resection is required, the
transposition or interposition of the splenic artery can, for
instance, be used for the reconstruction both of the hepatic
and superior mesenteric arteries [8, 46] (Fig. 2). In cases
when arterial reconstructions are undertaken, TP is gener-
ally performed [8, 45]. The complete removal of the pan-
creas makes the procedure safer by eliminating completely
the problem of pancreas fistula and it’s potentially fatal
effect on the arterial anastomosis.
Fig. 1 Picture of intraoperative pancreatoscopy. The pancreatoscope
is inserted in the main pancreatic duct after the transection of the
pancreatic neck in a pancreaticoduodenectomy procedure performed
for main-duct IPMN. SMV superior mesenteric vein
Fig. 2 Intraoperative picture of total pancreatectomy associated with
resection of the right hepatic artery (RHA) and reconstruction with
the splenic artery (SA) rotated. LGA left gastric artery, ICV inferior
cava vein, SMV superior mesenteric vein
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High-risk pancreatic anastomosis
A soft pancreatic texture and a small main pancreatic duct
represent the major risk factors for the development of
postoperative pancreatic fistula and these can easily be
evaluated pre- and intraoperatively [47]. Overweight and
pancreatic fat infiltration are other well-recognized pre-
dictors for the risk of postoperative fistula [48] and can as
well create a technical problem in making the pancreatic
anastomosis (Fig. 3). In selected cases of very high-risk
patients, with a high-risk pancreas and other contributing
risk factors, TP may represent an alternative to a pancreatic
anastomosis in an attempt to reduce the significant post-
operative morbidity and mortality. This approach has been
proposed recently, even in a conjunction to auto-islet
transplantation [9]. However, this decision should be
always weighted against the risks associated with TP, as
the postoperative mortality and morbidity (Table 1) of TP
are significant as well as the long-term sequels of this
operation [3].
Discussion
In the last years, the number of the performed TP for the
treatment of pancreatic diseases has been reduced in all
high-volume pancreatic centers. There are several reasons
for sustaining this trend. First of all, in oncologic surgery,
there is no evidence that TP represents a more radical
oncologic procedure [4]. [3]. In contrast, TP is associated
with short- and long-term serious sequels and complica-
tions due to the ‘‘brittle’’ diabetes – 3 % late mortality
caused by severe hypoglycaemia and chronic complica-
tions in the target organs.
However, even today, TP has its role in pancreatic
surgery for some limited indications. As previously dis-
cussed, for patients affected by chronic pancreatitis, in
whom the conventional medical and surgical approaches
have failed, TP can represent the only therapeutic alter-
native, particularly, in association with auto-islet trans-
plantation [10, 13] with encouraging results for pain,
metabolic control and postoperative quality of life. The
quantity of the islet cells and the timing of the procedure
are crucial for the success of the auto-islet transplantation.
TP for the treatment of precancerous lesions has been
decreasingly recommended as upfront approach, but rather
partial resections, with intraoperative frozen section of the
resection margin and/or pancreatoscopy to preserve pan-
creatic parenchyma [42]. However, in selected cases with
diffuse dysplastic changes in the duct, TP still represents
the best alternative for patients with main-duct IPMN.
In our experience, TP represents the best choice for
patients who undergo pancreatectomy with arterial resec-
tions and reconstructions. The complete removal of the
pancreas eliminates the risk of pancreatic fistula leading
potentially to postoperative pseudoaneurysms and late
erosive bleedings in the presence of simultaneous arterial
anastomosis.
TP cannot be considered an equal alternative to pan-
creatic anastomosis to reduce the pancreas remnant com-
plications, even with auto-islet transplantation, according
to the current level of evidence in literature. However, in
selected patients in poor general conditions, and with very
high-risk pancreas and obese, TP may represent an ade-
quate alternative technique [9].
In conclusion, even if the indications for TP have been
consistently reduced over time, even today this procedure
still has its place. The improvement of short- and long-term
results of TP when combined with auto-islet transplanta-
tion may expand the spectrum of indication for this pro-
cedure in the near future.
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